CROI 2010
Experimental Drug TMC207 Cuts Response Time for Multidrug-resistant Tuberculosis
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 05 October 2010 13:46
- Written by Liz Highleyman
Tibotec's investigational drug TMC207, added to a 5-drug combination regimen for 8 weeks, increased the cure rate for multidrug-resistant tuberculosis (MDR-TB) and reduced response time by more than half, according to study findings presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. A related report described good outcomes using meropenem/clavulanate in a small group of patients with extensively drug-resistant TB (XDR-TB).
|
|
CROI 2010: Risk Factors for Neurocognitive Impairment among People with HIV
- Details
- Category: Neurocognitive Problems
- Published on Tuesday, 06 April 2010 13:57
- Written by Liz Highleyman
People with higher blood and cerebrospinal fluid viral load and lower CD4 cell count are more likely to develop neurocognitive impairment, according to studies presented in February at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco. In addition, researchers with the SMART study reported that cardiovascular risk factors predict poorer neurocognitive performance. But conflicting findings emphasize the need for further research.
CROI 2010: Even Low-level, Short-term Detectable Viral Load Raises the Risk of Virological Treatment Failure and Death
- Details
- Category: HIV Disease Progression
- Published on Friday, 26 March 2010 13:57
- Written by Liz Highleyman
People with HIV who have persistent episodes of low-level viremia are more likely to experience sustained virological rebound and have a higher risk of death than individuals who maintain consistently undetectable viral load (< 50 copies/mL) or experience only transient "blips," according to a poster presented at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last month in San Francisco.
CROI 2010: HIV/HCV Coinfected Patients Demonstrate Poorer Neurocognitive Performance, but No Difference in Neural Imaging
- Details
- Category: Neurocognitive Problems
- Published on Tuesday, 06 April 2010 13:57
- Written by Liz Highleyman
HIV/HCV coinfected individuals with good HIV suppression on performed more poorly than HIV monoinfected people on neurocognitive tests, but the 2 groups showed no significant differences in neural imaging measures, according to a study presented at the recent 17th Conference on Retroviruses and Opportunistic Infections in San Francisco (CROI 2010).
CROI 2010: Vitamin D Deficiency is Widespread among People with HIV in U.S., Europe, and Africa
- Details
- Category: HIV Treatment
- Published on Friday, 19 March 2010 13:57
- Written by Liz Highleyman
Low levels of vitamin D are common among HIV positive people around the world, especially in seasons when people get less sun exposure, according to a series of studies presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) last month in San Francisco. Vitamin D deficiency promotes bone loss and has been linked to conditions including cardiovascular disease, cancer, and vaginal inflammation.
More Articles...
- CROI 2010: ART Intensification with Maraviroc (Selzentry) or Raltegravir (Isentress) May Improve Immune Activation and Inflammation
- CROI 2010: Inflammation and Immune Activation Linked to Increase Mortality Risk in People with HIV
- CROI 2010: HIV/HBV and HIV/HCV Coinfected People with Impaired Liver Function and Inflammation Have Higher Risk of Non-AIDS Death
- CROI 2010: IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
Web Design and Development by